Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rational evaluation of different lymph node dissection]

J Q Chen1, S B Wang, C L Qi

  • 1Cancer Institute, China Medical University, Shenyang.

Zhonghua Yi Xue Za Zhi
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Research advances on the mechanisms of PM<sub>2.5</sub> exposure induced brain region-selective injury and related disease associations].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Same author

[Transcript distribution, sequence characteristics and clinical outcomes of rare transcript types of BCR::ABL1 fusion gene-positive leukemia patients].

Zhonghua yi xue za zhi·2026
Same author

[Molecular mechanisms of the TRPV4-RhoA/ROCK1 signaling axis in mediating mechanical stress-induced myocardial fibrosis in fetuses with tetralogy of Fallot].

Zhonghua xin xue guan bing za zhi·2026
Same author

[A case of severe congenital tuberculosis].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2026
Same author

Phylogeny and taxonomy of <i>Acer</i> powdery mildews, including genera <i>Sawadaea</i> and <i>Takamatsuella</i> (<i>Erysiphaceae, Ascomycota</i>).

Studies in mycology·2026
Same author

[Tripartite fusion gene: a novel discovery in the pathogenesis and drug resistance of atypical acute promyelocytic leukemia].

Zhonghua yi xue za zhi·2025
Same journal

[Clinical analysis of ultrasound-guided percutaneous sclerotherapy combined with radiofrequency ablation in the treatment of intrahepatic biliary cystadenoma].

Zhonghua yi xue za zhi·2026
Same journal

[Metabolic profiles in umbilical cord blood associated with neonatal brain injury in selective fetal growth restriction].

Zhonghua yi xue za zhi·2026
Same journal

[Relationship between the consistency of auxiliary provocation tests with the supine roll test and treatment outcomes for horizontal semicircular canal benign paroxysmal positional vertigo].

Zhonghua yi xue za zhi·2026
Same journal

[Early-and mid-trimester glycolipid metabolism indicators for predicting adverse pregnancy outcomes in normoglycemic women].

Zhonghua yi xue za zhi·2026
Same journal

[Value of a deep learning-based visual model for predicting postoperative upper limb functional recovery after severe acute cervical spinal cord injury].

Zhonghua yi xue za zhi·2026
Same journal

[Eosinophils and futile recanalization after thrombectomy in acute large vessel occlusion stroke: the mediating effect of malignant brain edema].

Zhonghua yi xue za zhi·2026
See all related articles

The extent of lymph node dissection for gastric cancer depends on the stage and metastasis. D2 or D3 dissection offers better outcomes for advanced stages or significant lymph node involvement, while less extensive procedures suffice for early stages.

Area of Science:

  • Surgical Oncology
  • Gastroenterology
  • Oncology

Context:

  • Gastric cancer treatment involves surgical resection with varying lymph node dissection (LND) strategies.
  • The optimal extent of LND (D1+, D2, D3) remains a critical consideration for improving patient survival rates.

Purpose:

  • To evaluate the efficacy and indications of different lymph node dissection levels (D1+, D2, D3) in radical surgeries for gastric cancer.
  • To correlate LND extent with tumor stage, type, and lymph node metastasis for optimized treatment selection.

Summary:

  • A study of 371 gastric cancer cases indicated D1+ or D1 LND for Ia stage, D2 for Ib stage.
  • D2 or D3 LND demonstrated superior outcomes for localized/massive II+III stage gastric cancer compared to D1+.
  • For advanced IV stage gastric cancer of the same type, D3+D2 dissection yielded a 5-year survival rate of 42.9%.

Related Experiment Videos

  • Extended LND (D3/D2) showed limited benefit for infiltrative/diffuse types in II+III or IV stages, especially without metastasis.
  • LND extent should be guided by metastasis: D2/D3 for limited metastasis (1st group), D3 for 2nd group or more extensive metastasis, with diminishing returns for extensive metastasis (beyond 10 nodes or 3rd group).

    • Impact:

    • Provides evidence-based recommendations for tailoring lymph node dissection extent in gastric cancer surgery.
    • Aims to improve surgical decision-making, potentially enhancing patient survival and reducing unnecessary surgical morbidity.
    • Contributes to refining treatment guidelines for gastric cancer based on clinicopathological factors.